SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWarpaint London Regulatory News (W7L)

Share Price Information for Warpaint London (W7L)

Share Price is delayed by 15 minutes
Get Live Data
212.50    -2.50 (-1.16%)
Bid:
210.00
Ask:
215.00
Spread: 5.00 (2.381%)
Market Cap: £171.67m
W7L Live PriceLast checked at - London Stock Exchange

Intraday Warpaint London Share Chart

Form 8.5 (EPT/RI)

20 Jan 2025 11:02

RNS Number : 9740T
Singer Capital Markets Sec Ltd
20 January 2025
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Singer Capital Markets Securities Ltd

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

WARPAINT LONDON PLC

 

(c) Name of the party to the offer with which exempt principal trader is connected:

BRAND ARCHITEKTS GROUP PLC

(d) Date dealing undertaken:

17 January 2025

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

YES

If YES, specify which:

 

BRAND ARCHITEKTS GROUP PLC

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

Purchases

 

7,740

 

513.1p

 

513.1p

 

ORD 25p

 

Sales

 

2,883

 

514p

 

514p

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

20 January 2025

Contact name:

Cindy Le

Telephone number:

020 7496 3171

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERURRARVRUAUAR
Date   Source Headline
24th Mar 20237:00 amRNSTrading Update and Notice of Results
14th Feb 202310:16 amRNSAIM Rule 17 Notification
11th Jan 20237:00 amRNSFull Year Trading Update
3rd Jan 20237:00 amRNSResignation of Non-Executive Director
14th Oct 20227:00 amRNSRenewal of New Moorcroft House lease at Silsden
21st Sep 20227:00 amRNSInterim Results
16th Sep 20227:00 amRNSChange of Adviser
8th Sep 20224:40 pmRNSSecond Price Monitoring Extn
8th Sep 20224:36 pmRNSPrice Monitoring Extension
8th Sep 20222:06 pmRNSSecond Price Monitoring Extn
8th Sep 20222:00 pmRNSPrice Monitoring Extension
8th Sep 202211:05 amRNSSecond Price Monitoring Extn
8th Sep 202211:00 amRNSPrice Monitoring Extension
8th Sep 20227:00 amRNSTrading Update
1st Sep 20227:00 amRNSNotice of Results and Investor Webinar
29th Jun 20227:00 amRNSPMDR / PCA Dealing
28th Jun 20227:00 amRNSDirector/PDMR Dealing
27th Jun 202211:34 amRNSResult of AGM
27th Jun 20227:00 amRNSAGM Statement
31st May 20227:00 amRNSNotice of AGM and Posting of Annual Report
26th Apr 20223:57 pmRNSDividend Timetable
26th Apr 20227:00 amRNSResults for the year ended 31 December 2021
12th Apr 20227:00 amRNSTrading Update and Notice of Results
21st Mar 20221:21 pmRNSHolding(s) in Company
11th Mar 20225:23 pmRNSPMDR / PCA Dealing
2nd Mar 20227:00 amRNSWard & Hagon Contract Renewal and Grant of Options
28th Feb 20224:29 pmRNSHolding(s) in Company
23rd Feb 20224:56 pmRNSHolding(s) in Company
1st Feb 20227:00 amRNSFull Year Trading Update
2nd Nov 20217:00 amRNSTrading Update
22nd Sep 20217:00 amRNSInterim Results
16th Sep 202112:16 pmRNSPrice Monitoring Extension
14th Sep 20219:05 amRNSSecond Price Monitoring Extn
14th Sep 20219:00 amRNSPrice Monitoring Extension
1st Sep 20217:00 amRNSNotice of Results & Investor Webinar
3rd Aug 20217:00 amRNSAppointment of Non-Executive Director
11th Jun 202111:24 amRNSResult of AGM
11th Jun 202111:05 amRNSSecond Price Monitoring Extn
11th Jun 202111:00 amRNSPrice Monitoring Extension
11th Jun 20217:00 amRNSAGM Statement
28th May 202111:01 amRNSTotal Voting Rights
25th May 20213:28 pmRNSGrant of Options and Director/PDMR Shareholding
17th May 202112:34 pmRNSNotice of AGM and Posting of Annual Report
6th May 20213:57 pmRNSExercise of share options, issue of equity and TVR
28th Apr 20217:00 amRNSResults for the year ended 31 December 2020
20th Apr 20214:41 pmRNSSecond Price Monitoring Extn
20th Apr 20214:36 pmRNSPrice Monitoring Extension
20th Apr 20217:00 amRNSTrading Update and Notice of Results
19th Apr 20212:26 pmRNSHolding(s) in Company
8th Mar 20214:37 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.